Welcome to our dedicated page for NVTA news (Ticker: NVTA), a resource for investors and traders seeking the latest updates and insights on NVTA stock.
This page aggregates news and press releases related to Invitae (OTC: NVTA), a medical genetics company that focuses on clinical genetic testing, variant classification, and genomic data research. The news coverage reflects Invitaes role in medical laboratories, health care, and social assistance, as well as its corporate and financial developments.
Company announcements describe Invitae as a provider of genetic information that aims to deliver accurate and actionable results to support medical decision-making. News items include updates on research presented at professional meetings, such as the American College of Medical Genetics and Genomics Annual Clinical Genetics Meeting and the American Society of Breast Surgeons Annual Meeting. These stories highlight work on variant reclassification, machine learning models for hereditary cancer and Lynch syndrome genes, and studies of variants of uncertain significance and their impact on clinical management.
Other articles focus on Invitaes technology platforms and data resources, including the Invitae Generation platform and Clinical Variant Modeling, which the company describes as using machine learning and large genomic datasets to improve variant classification. News also covers collaborations with biopharmaceutical partners, such as an agreement with BridgeBio Pharma to use Invitaes rare disease enriched dataset and analytical capabilities for genetics-based drug discovery.
In addition to scientific and product-related updates, the news feed includes major corporate events. These include Invitaes filing for voluntary chapter 11 protection in the U.S. Bankruptcy Court for the District of New Jersey, its court-supervised sale process, and the selection of Labcorp as the winning bidder to acquire substantially all of the companys assets, subject to approvals. Asset transactions involving specific business lines, such as the transfer of certain reproductive health assets to Natera, also appear in coverage.
Investors, clinicians, and others interested in NVTA can use this page to review historical and ongoing developments in Invitaes research activities, technology initiatives, partnerships, restructuring efforts, and asset sales as reported in public news sources.
Invitae (NYSE: NVTA) will announce its second quarter 2022 financial results on August 9, 2022. A conference call will follow at 4:30 p.m. Eastern / 1:30 p.m. Pacific to discuss these results and other recent highlights. Investors can register for the call and access a live webcast through the company’s website or the provided link. Invitae aims to improve healthcare by integrating genetic information into mainstream medical practice, focusing on faster, higher quality, and more affordable genetic testing.
Invitae (NYSE: NVTA) announced a strategic business realignment to prioritize higher-margin initiatives, with expected non-GAAP cost savings of approximately $326 million by 2023. The operational shift will eliminate non-core businesses and streamline processes to extend the firm's cash runway to the end of 2024. Preliminary results for Q2 2022 indicate revenues of around $136 million and a GAAP gross margin of 18-19%. The company expects revenue growth to stabilize during the second half of 2022, aiming for a future growth rate of 15-25% beyond 2023.
Invitae (NYSE: NVTA) announces a leadership transition with Kenneth D. Knight stepping in as CEO, succeeding Sean George, who remains on the Board. Co-founder Randy Scott returns as chairman, enhancing strategic guidance. Knight aims to refocus on profitable business lines and increase operational efficiency, fostering margin growth and extending the company's cash runway. The board expresses confidence in Knight's capabilities due to his prior success as COO and extensive industry experience, expecting a positive shift towards cash flow positivity.
Worldwide Clinical Trials has partnered with Invitae to enhance clinical trials for rare diseases using Invitae's Explorer tool, which offers access to aggregated genetic testing data. This collaboration targets the estimated 300 million individuals suffering from rare diseases globally, enabling faster patient recruitment and improved trial strategies. With globally recognized expertise, Worldwide aims to leverage genetic insights to optimize study locations and strategies, ultimately aiming to provide impactful treatments for rare diseases.
Invitae (NYSE: NVTA), a prominent medical genetics company, announced its participation in two investor conferences. The 42nd Annual William Blair Growth Stock Conference will take place on June 7, 2022, at 8:40 a.m. CT in Chicago. The 43rd Annual Goldman Sachs Global Healthcare Conference is scheduled for June 15, 2022, at 2:40 p.m. PT in Rancho Palos Verdes, CA. Live webcasts for these presentations can be accessed on the company's investor website with replays available post-event.
Invitae (NYSE: NVTA) will present eight studies at the 2022 ASCO Annual Meeting highlighting the critical role of genetic testing for all cancer patients. Key findings indicate that 15% of melanoma patients carry inherited variants linked to cancer syndromes, necessitating universal genetic testing. The research also reveals that 50% of pathogenic variants in prostate cancer patients could be overlooked under current guidelines. Additionally, a study of colorectal cancer patients shows 13% possess inherited variants affecting treatment eligibility, emphasizing the need for updated testing strategies.
Invitae reported a 19.4% increase in revenue to $123.7 million for Q1 2022 compared to the same quarter in 2021. The company ended the quarter with $885 million in cash and reduced cash burn by $26 million, totaling $169 million. Total operating expenses rose to $239.8 million, with a net loss of $181.9 million, or $0.80 per share. Invitae aims for positive operating cash flow by the end of 2025 while driving growth and reducing operational expenditures by $600 million over three years.
Allelica has partnered with Invitae Corporation (NYSE: NVTA) to develop a clinical artificial intelligence architecture that focuses on breast cancer polygenic risk scores (PRS) tailored for various genetic ancestries. This collaboration aims to close the diversity gap in genomic medicine and improve early breast cancer detection. By integrating Invitae's extensive genomic data with Allelica's analytics, the initiative seeks to create a new PRS, benefiting women at increased risk due to family history. The partnership addresses unmet needs in hereditary cancer testing.
Invitae Corporation (NYSE: NVTA) is set to release its first quarter 2022 financial results on May 3, 2022, at 4:30 p.m. Eastern. The company will conduct a conference call and webcast to discuss its financial performance and recent developments. Interested participants can register for the call through the provided link. Invitae aims to simplify access to genetic information to enhance healthcare quality globally.
Invitae (NYSE: NVTA) has launched a groundbreaking Neurodevelopmental Disorders (NDD) testing package, designed to provide essential genetic insights for children with developmental disabilities. This package uniquely combines chromosomal microarray analysis, fragile X-related disorder analysis, and a panel of over 200 genes related to neurodevelopmental disorders. Notably, Invitae is the only company offering these tests in one accessible package with a rapid turnaround of 10-21 days. The NDD package aims to address the gap in genetic testing among children, supported by guidelines from the American Academy of Pediatrics.